Smruthi Organics Ltd
Incorporated in 1989, Smruthi Organics Ltd
is a manufacturer of Active Pharmaceutical Ingredients[1]
- Market Cap ₹ 139 Cr.
- Current Price ₹ 121
- High / Low ₹ 169 / 103
- Stock P/E 29.7
- Book Value ₹ 61.9
- Dividend Yield 1.24 %
- ROCE 7.98 %
- ROE 5.04 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 50.5%
Cons
- The company has delivered a poor sales growth of -0.78% over past five years.
- Company has a low return on equity of 5.44% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92 | 77 | 74 | 79 | 97 | 137 | 131 | 126 | 133 | 141 | 128 | 126 | 120 | |
| 90 | 72 | 63 | 69 | 94 | 121 | 116 | 98 | 115 | 131 | 116 | 114 | 106 | |
| Operating Profit | 2 | 5 | 11 | 10 | 3 | 17 | 15 | 29 | 18 | 10 | 12 | 12 | 14 |
| OPM % | 2% | 6% | 14% | 13% | 3% | 12% | 12% | 23% | 14% | 7% | 9% | 10% | 12% |
| 1 | 0 | 0 | 1 | 0 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Interest | 5 | 6 | 5 | 4 | 4 | 4 | 3 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 6 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 | 6 |
| Profit before tax | -9 | -6 | 2 | 3 | -5 | 10 | 12 | 24 | 14 | 4 | 5 | 5 | 6 |
| Tax % | -32% | -33% | 55% | 39% | -31% | 30% | 30% | 29% | 25% | 8% | 28% | 27% | |
| -6 | -4 | 1 | 2 | -3 | 7 | 8 | 17 | 10 | 4 | 4 | 4 | 5 | |
| EPS in Rs | -5.39 | -3.34 | 0.63 | 1.39 | -2.82 | 6.02 | 7.41 | 14.95 | 9.07 | 3.61 | 3.14 | 3.11 | 4.08 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 14% | 20% | 33% | 55% | 48% | 48% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -1% |
| 3 Years: | -2% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -16% |
| 3 Years: | -30% |
| TTM: | 613% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -12% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 31 | 26 | 27 | 28 | 25 | 33 | 39 | 49 | 56 | 57 | 58 | 60 | 59 |
| 43 | 45 | 37 | 33 | 31 | 28 | 16 | 10 | 3 | 6 | 12 | 17 | 9 | |
| 48 | 34 | 35 | 20 | 25 | 37 | 30 | 21 | 18 | 32 | 37 | 23 | 20 | |
| Total Liabilities | 126 | 109 | 103 | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 112 | 100 |
| 41 | 35 | 32 | 30 | 30 | 30 | 32 | 31 | 33 | 37 | 40 | 45 | 46 | |
| CWIP | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 3 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 83 | 72 | 69 | 54 | 54 | 69 | 56 | 60 | 53 | 66 | 77 | 64 | 49 | |
| Total Assets | 126 | 109 | 103 | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 112 | 100 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 9 | 14 | 9 | 5 | 12 | 21 | 23 | 2 | 12 | 4 | 10 | |
| -2 | -1 | 0 | -0 | -3 | -4 | -5 | -3 | 7 | -10 | -7 | -11 | |
| -6 | -8 | -14 | -9 | -2 | -5 | -17 | -7 | -12 | -2 | 3 | 1 | |
| Net Cash Flow | 2 | -1 | -0 | 0 | 0 | 2 | -1 | 13 | -3 | 0 | -0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 103 | 95 | 97 | 95 | 97 | 68 | 62 | 78 | 96 | 117 | 94 |
| Inventory Days | 133 | 123 | 166 | 145 | 126 | 92 | 75 | 100 | 91 | 96 | 150 | 151 |
| Days Payable | 132 | 106 | 128 | 123 | 130 | 120 | 97 | 81 | 50 | 98 | 144 | 85 |
| Cash Conversion Cycle | 104 | 120 | 133 | 119 | 92 | 68 | 46 | 80 | 118 | 93 | 123 | 160 |
| Working Capital Days | -8 | 2 | 8 | 1 | 7 | 78 | 32 | 52 | 99 | 73 | 94 | 92 |
| ROCE % | -5% | 0% | 9% | 10% | -1% | 21% | 25% | 39% | 21% | 7% | 8% | 8% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Nov
- Financial Results For Quarter And Half Year Ended 30Th September 2025 11 Nov
-
Board Meeting Outcome for Quarterly Results For Second Quarter And Half Year Ended 30Th September, 2025
11 Nov - Unaudited results for quarter/half-year ended 30-09-2025: Q2 net profit Rs205.62L; H1 net profit Rs96.07L; H1 revenue Rs5,068.52L.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR) Regulations, 2015
31 Oct - Board meeting 11 Nov 2025 to approve Q2/H1 un-audited results ended 30 Sep 2025; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations for quarter ended 30th September, 2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
SOL is in the pharmaceutical business with presence in manufacturing bulk drugs and active pharmaceutical ingredients